Ikarian Capital, LLC Gamida Cell Ltd. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.73 - $4.29 $56,551 - $140,235	-32,689 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.22 - $4.47 $3,685 - $7,420	1,660 Added 5.35%	32,689 $135,000
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $527 - $882	-137 Reduced 0.44%	31,029 $122,000
Q2 2021 Aug 16, 2021	SELL	$5.85 - $8.33 $614,109 - $874,450	-104,976 Reduced 77.11%	31,166 $201,000
Q1 2021 May 17, 2021	SELL	$7.8 - $12.43 $186,092 - $296,554	-23,858 Reduced 14.91%	136,142 $1.1 Million
Q4 2020 Feb 12, 2021	BUY	$4.07 - $11.0 $651,200 - $1.76 Million	160,000 New	160,000 $1.34 Million

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.